Insights
Search Results
Client Highlights
3.27.26
Wilson Sonsini Advises Excellergy on $2 Billion Acquisition by Novartis
On March 27, 2026, Excellergy, a biotechnology company developing a novel class of allergy therapeutics, announced it will be acquired by Novartis in a transaction with a total potential value of up to $2 billion in upfront and milestone payments. The acquisition brings together Excellergy's novel trifunctional ECRIs with the development expertise of Novartis. Wilson Sonsini Goodrich & Rosati advised Excellergy on the transaction.
Client Highlights
1.14.26
Wilson Sonsini Advises Polygon Labs on Acquisitions of Coinme and Sequence
On January 13, 2026, Polygon Labs announced definitive agreements to acquire Coinme and Sequence for more than $250 million to expand into regulated stablecoin payments in the U.S. Both companies will play foundational roles in building Polygon's forthcoming Open Money Stack, which aims to facilitate instant and reliable money movement. The Polygon Open Money Stack includes physical cash and digital fiat on- and off-ramps, wallet infrastructure, and cross-chain orchestration through intents. Wilson Sonsini Goodrich & Rosati is advising Polygon on both transactions.
Client Highlights
12.08.25
Wilson Sonsini Advises Foresight Diagnostics on Acquisition by Natera
On December 5, 2025, Natera, Inc., a global leader in cell-free DNA and precision medicine, and Foresight Diagnostics, a leader in ultrasensitive molecular residual disease (MRD) detection, announced that Natera has completed its acquisition of Foresight in an all-stock transaction consisting of a $275 million upfront payment with an additional $175 million in earnouts tied to the achievement of revenue- and reimbursement-based milestones. Wilson Sonsini Goodrich & Rosati advised Foresight on the transaction.
The transaction combines Natera’s leading commercial and operational infrastructure for the delivery of personalized MRD testing with Foresight’s unique phased variant technology and leadership in lymphoma. It builds on Natera’s broad intellectual property portfolio for tumor-informed and personalized MRD products including in phased variants, and promises to accelerate MRD adoption in lymphoma and other solid tumor types.
The transaction combines Natera’s leading commercial and operational infrastructure for the delivery of personalized MRD testing with Foresight’s unique phased variant technology and leadership in lymphoma. It builds on Natera’s broad intellectual property portfolio for tumor-informed and personalized MRD products including in phased variants, and promises to accelerate MRD adoption in lymphoma and other solid tumor types.
Client Highlights
7.25.25
Wilson Sonsini Advises Cooler Heads on $11 Million Series A
On July 22, 2025, Cooler Heads announced that it has closed an oversubscribed $11 million Series A funding round to expand the manufacturing and rollout of Amma™, the only FDA-cleared Portable Scalp Cooling System. The financing was led by Mutual Capital Partners, a Cleveland healthtech-focused venture capital fund, with participation from SHD Partners, Crescent Ridge VC, Cal Innovation Fund, NuFund, Robin Hood Ventures, Golden Seeds, HIP VC, and an unnamed strategic investor. Wilson Sonsini Goodrich & Rosati advised Cooler Heads on the transaction.
The Amma™ system helps chemotherapy patients keep their hair and preserve their privacy, eliminating the disfiguring hair loss that has long been an accepted side effect of chemotherapy. The proceeds from the Series A financing will be used to increase manufacturing capacity, expand the commercial team, and develop the next generation of the product.
The Wilson Sonsini team that advised Cooler Heads on the transaction included Karen Deschaine, Phil McGill, Dani Glazer Signaigo, and Matt Fleming.
For more information, please see the Cooler Heads news release.
The Amma™ system helps chemotherapy patients keep their hair and preserve their privacy, eliminating the disfiguring hair loss that has long been an accepted side effect of chemotherapy. The proceeds from the Series A financing will be used to increase manufacturing capacity, expand the commercial team, and develop the next generation of the product.
The Wilson Sonsini team that advised Cooler Heads on the transaction included Karen Deschaine, Phil McGill, Dani Glazer Signaigo, and Matt Fleming.
For more information, please see the Cooler Heads news release.
Client Highlights
8.23.24
Wilson Sonsini Advises Borealis Biosciences on $150 Million Series A and Strategic Collaboration Funding
On August 22, 2024, Borealis Biosciences (Borealis), a next-generation RNA medicines company, emerged from stealth with $150 million in combined Series A financing from founding investor Versant Ventures and Novartis AG, as well as committed strategic research collaboration funding from Novartis. Wilson Sonsini Goodrich & Rosati advised Borealis on the transaction.
Bylined Articles
4.22.24
The Blake Brief: A Hitchhiker’s Guide to Patent Law in Outer Space
SatMagazine’s latest Blake Brief article, titled "A Hitchhiker’s Guide to Patent Law in Outer Space" and authored by Curt Blake, John Wehrli, Peter Bratton, Magnus Gan, James Dunlop, and Matthew Fleming, discusses the value of conducting pharmaceutical research and development in space. The article specifically examines Merck's development of "space crystals" for its blockbuster Keytruda antibody drug and suggests that future commercial space treaties should be flexible to navigate the questions and complexities around patenting inventions developed in space.